BioMimetic Ramps Up R&D For Synthetic Bone Products
This article was originally published in The Gray Sheet
Executive Summary
Combination products firm BioMimetic expects rapid enrollment this fall in a U.S. pivotal study of a product to facilitate fusions in the foot and ankle, CEO Samuel Lynch said during an Aug. 14 earnings call